CSNpharm

CSNpharm logo

Csnpharm is committed to providing you with high quality products and outstanding services. We supply over 5000 bioactive compounds in stock, including inhibitors, agonists and natural products for laboratory and scientific use. Csnpharm has always been committed to develop quality products that are validated by NMR, UPLC, LC-MS, GC, Chiral HPLC and so on. We have a professional technical support team for customer service with years of experience in life science. Csnpharm is your reliable partner for scientific research.

Company Website

Product Listing

Yatein 1mg  | ≥98%

CSNpharm

Yatein, a lignan precursor of podophyllotoxin isolated and purified from the leaves of Chamaecyparis obtusa, is a key agent in anticancer drugs and can significantly suppress HSV-1 multiplication in HeLa cells without apparent cytotoxicity.

More Information Supplier Page

YC-1 10mg  | ≥99%

CSNpharm

Lificiguat is an acivator of guanylyl cyclase (sGC) and can bind to the heme-containing domain of the β subunit with Kd of 0.6 μM – 1.1 μM.

More Information Supplier Page

YC-1 250mg  | ≥99%

CSNpharm

Lificiguat is an acivator of guanylyl cyclase (sGC) and can bind to the heme-containing domain of the β subunit with Kd of 0.6 μM – 1.1 μM.

More Information Supplier Page

YC-1 5mg  | ≥99%

CSNpharm

Lificiguat is an acivator of guanylyl cyclase (sGC) and can bind to the heme-containing domain of the β subunit with Kd of 0.6 μM – 1.1 μM.

More Information Supplier Page

YC-1 50mg  | ≥99%

CSNpharm

Lificiguat is an acivator of guanylyl cyclase (sGC) and can bind to the heme-containing domain of the β subunit with Kd of 0.6 μM – 1.1 μM.

More Information Supplier Page

YC-1 100mg  | ≥99%

CSNpharm

Lificiguat is an acivator of guanylyl cyclase (sGC) and can bind to the heme-containing domain of the β subunit with Kd of 0.6 μM – 1.1 μM.

More Information Supplier Page

YL-109 50mg  | ≥99%

CSNpharm

YL-109 is an anticancer agent with ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo.

More Information Supplier Page

YL-109 25mg  | ≥99%

CSNpharm

YL-109 is an anticancer agent with ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo.

More Information Supplier Page

YL-109 5mg  | ≥99%

CSNpharm

YL-109 is an anticancer agent with ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo.

More Information Supplier Page

YL-109 10mg  | ≥99%

CSNpharm

YL-109 is an anticancer agent with ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo.

More Information Supplier Page

YL-109 1mg  | ≥99%

CSNpharm

YL-109 is an anticancer agent with ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo.

More Information Supplier Page

YM 976 10mg  | ≥99%

CSNpharm

YM976 is an orally active PDE4 inhibitor (IC50 = 2.2 nM). YM976 has low emetogenic activity, suggested to be due to poor brain penetration.

More Information Supplier Page

YM 976 5mg  | ≥99%

CSNpharm

YM976 is an orally active PDE4 inhibitor (IC50 = 2.2 nM). YM976 has low emetogenic activity, suggested to be due to poor brain penetration.

More Information Supplier Page

YM 976 1mg  | ≥99%

CSNpharm

YM976 is an orally active PDE4 inhibitor (IC50 = 2.2 nM). YM976 has low emetogenic activity, suggested to be due to poor brain penetration.

More Information Supplier Page

YM-58483 50mg  | ≥99%

CSNpharm

YM-58483 is a selective and potent blocker of store-operated Ca2+ entry (SOCE), which can regulate the activation of non-excitable cells such as lymphocytes.

More Information Supplier Page

YM-58483 2mg  | ≥99%

CSNpharm

YM-58483 is a selective and potent blocker of store-operated Ca2+ entry (SOCE), which can regulate the activation of non-excitable cells such as lymphocytes.

More Information Supplier Page

YM-58483 5mg  | ≥99%

CSNpharm

YM-58483 is a selective and potent blocker of store-operated Ca2+ entry (SOCE), which can regulate the activation of non-excitable cells such as lymphocytes.

More Information Supplier Page

YM-58483 100mg  | ≥99%

CSNpharm

YM-58483 is a selective and potent blocker of store-operated Ca2+ entry (SOCE), which can regulate the activation of non-excitable cells such as lymphocytes.

More Information Supplier Page

YM-58483 25mg  | ≥99%

CSNpharm

YM-58483 is a selective and potent blocker of store-operated Ca2+ entry (SOCE), which can regulate the activation of non-excitable cells such as lymphocytes.

More Information Supplier Page

YM-58483 10mg  | ≥99%

CSNpharm

YM-58483 is a selective and potent blocker of store-operated Ca2+ entry (SOCE), which can regulate the activation of non-excitable cells such as lymphocytes.

More Information Supplier Page

YM-90709 5mg  | ≥99%

CSNpharm

YM-90709 is a competitive and selective IL-5 receptor antagonist with IC50 value ranging in 0.45 – 1 mM.

More Information Supplier Page

YM-90709 10mg  | ≥99%

CSNpharm

YM-90709 is a competitive and selective IL-5 receptor antagonist with IC50 value ranging in 0.45 – 1 mM.

More Information Supplier Page

YM-90709 1mg  | ≥99%

CSNpharm

YM-90709 is a competitive and selective IL-5 receptor antagonist with IC50 value ranging in 0.45 – 1 mM.

More Information Supplier Page

YM-90709 50mg  | ≥99%

CSNpharm

YM-90709 is a competitive and selective IL-5 receptor antagonist with IC50 value ranging in 0.45 – 1 mM.

More Information Supplier Page

YM-90709 25mg  | ≥99%

CSNpharm

YM-90709 is a competitive and selective IL-5 receptor antagonist with IC50 value ranging in 0.45 – 1 mM.

More Information Supplier Page

YO-01027 10mg  | ≥99%

CSNpharm

Dibenzazepine is a dipeptidic γ-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM in cell-free assays for APPL and Notch cleavage, respectively.

More Information Supplier Page

YO-01027 2mg  | ≥99%

CSNpharm

Dibenzazepine is a dipeptidic γ-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM in cell-free assays for APPL and Notch cleavage, respectively.

More Information Supplier Page

YO-01027 25mg  | ≥99%

CSNpharm

Dibenzazepine is a dipeptidic γ-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM in cell-free assays for APPL and Notch cleavage, respectively.

More Information Supplier Page

YO-01027 5mg  | ≥99%

CSNpharm

Dibenzazepine is a dipeptidic γ-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM in cell-free assays for APPL and Notch cleavage, respectively.

More Information Supplier Page

YZ9 250mg  | ≥98%

CSNpharm

YZ9 is a PFKFB3 inhibitor with IC50 of 0.183 μM, also inhibits F-6-P with Ki of 0.094 μM.

More Information Supplier Page